Joseph Y Ting1, Anne Synnes1, Ashley Roberts1, Akhil Deshpandey2, Kimberly Dow3, Eugene W Yoon4, Kyong-Soon Lee5, Simon Dobson1, Shoo K Lee5, Prakesh S Shah5. 1. Department of Pediatrics, University of British Columbia, Vancouver, Canada. 2. Janeway Children's Health and Rehabilitation Centre, Saint John's, Newfoundland, Canada. 3. Department of Pediatrics, Kingston General Hospital and Queen's University, Kingston, Ontario, Canada. 4. Maternal-Infant Care Research Centre, Mount Sinai Hospital, Toronto, Ontario, Canada. 5. Maternal-Infant Care Research Centre, Mount Sinai Hospital, Toronto, Ontario, Canada5Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada.
Abstract
Importance: Excessive antibiotic use has been associated with altered bacterial colonization and may result in antibiotic resistance, fungemia, necrotizing enterocolitis (NEC), and mortality. Exploring the association between antibiotic exposure and neonatal outcomes other than infection-related morbidities may provide insight on the importance of rational antibiotic use, especially in the setting of culture-negative neonatal sepsis. Objective: To evaluate the trend of antibiotic use among all hospitalized very low-birth-weight (VLBW) infants across Canada and the association between antibiotic use rates (AURs) and mortality and morbidity among neonates without culture-proven sepsis or NEC. Design, Setting, and Participants: A retrospective cohort study was conducted among VLBW infants (<1500 g) admitted to level III neonatal intensive care units between January 1, 2010, and December 31, 2014, using data obtained from the Canadian Neonatal Network database. Exposure: Duration of antibiotic use during the hospitalization period. Main Outcomes and Measures: The AUR was defined as the number of days an infant was exposed to 1 or more antimicrobial agents divided by the total length of hospital stay. The composite primary outcome was defined as mortality or major morbidity, including any of the following: persistent periventricular echogenicity or echolucency on neuroimaging, chronic lung disease, and stage 3 or higher retinopathy of prematurity. Multivariable regression analysis was used to calculate adjusted odds ratios (aORs) and 95% CIs for the association between AURs and outcomes. Results: Among 13 738 eligible VLBW infants, 11 669 (84.9%) (mean [SD] gestational age, 27.7 [2.5] weeks; 47.4% female) received antibiotics during their hospital course and were included in the study. The annual AUR decreased from 0.29 in 2010 to 0.25 in 2014 (slope for the best-fit line, -0.011; 95% CI, -0.016 to -0.006; P < .01), which occurred in parallel with a reduction in the rate of late-onset sepsis from 19.0% in 2010 to 13.8% in 2014 during the same period. Of the 11 669 infants who were treated with antibiotics of varying duration during their hospital stay, 2845 were diagnosed as having sepsis-related complications. Among the remaining 8824 infants without early-onset sepsis, late-onset sepsis, or NEC, a 10% increase in the AUR was associated with an increased odds of the primary composite outcome (aOR, 1.18; 95% CI, 1.13-1.23), mortality (aOR, 2.04; 95% CI, 1.87-2.21), and stage 3 or higher retinopathy of prematurity (aOR, 1.18; 95% CI, 1.06-1.32). Conclusions and Relevance: Antibiotic use in VLBW infants decreased between 2010 and 2014 in Canada. However, among infants without culture-proven sepsis or without NEC, higher AURs were associated with adverse neonatal outcomes.
Importance: Excessive antibiotic use has been associated with altered bacterial colonization and may result in antibiotic resistance, fungemia, necrotizing enterocolitis (NEC), and mortality. Exploring the association between antibiotic exposure and neonatal outcomes other than infection-related morbidities may provide insight on the importance of rational antibiotic use, especially in the setting of culture-negative neonatal sepsis. Objective: To evaluate the trend of antibiotic use among all hospitalized very low-birth-weight (VLBW) infants across Canada and the association between antibiotic use rates (AURs) and mortality and morbidity among neonates without culture-proven sepsis or NEC. Design, Setting, and Participants: A retrospective cohort study was conducted among VLBW infants (<1500 g) admitted to level III neonatal intensive care units between January 1, 2010, and December 31, 2014, using data obtained from the Canadian Neonatal Network database. Exposure: Duration of antibiotic use during the hospitalization period. Main Outcomes and Measures: The AUR was defined as the number of days an infant was exposed to 1 or more antimicrobial agents divided by the total length of hospital stay. The composite primary outcome was defined as mortality or major morbidity, including any of the following: persistent periventricular echogenicity or echolucency on neuroimaging, chronic lung disease, and stage 3 or higher retinopathy of prematurity. Multivariable regression analysis was used to calculate adjusted odds ratios (aORs) and 95% CIs for the association between AURs and outcomes. Results: Among 13 738 eligible VLBW infants, 11 669 (84.9%) (mean [SD] gestational age, 27.7 [2.5] weeks; 47.4% female) received antibiotics during their hospital course and were included in the study. The annual AUR decreased from 0.29 in 2010 to 0.25 in 2014 (slope for the best-fit line, -0.011; 95% CI, -0.016 to -0.006; P < .01), which occurred in parallel with a reduction in the rate of late-onset sepsis from 19.0% in 2010 to 13.8% in 2014 during the same period. Of the 11 669 infants who were treated with antibiotics of varying duration during their hospital stay, 2845 were diagnosed as having sepsis-related complications. Among the remaining 8824 infants without early-onset sepsis, late-onset sepsis, or NEC, a 10% increase in the AUR was associated with an increased odds of the primary composite outcome (aOR, 1.18; 95% CI, 1.13-1.23), mortality (aOR, 2.04; 95% CI, 1.87-2.21), and stage 3 or higher retinopathy of prematurity (aOR, 1.18; 95% CI, 1.06-1.32). Conclusions and Relevance: Antibiotic use in VLBW infants decreased between 2010 and 2014 in Canada. However, among infants without culture-proven sepsis or without NEC, higher AURs were associated with adverse neonatal outcomes.
Authors: Sagori Mukhopadhyay; Karen M Puopolo; Nellie I Hansen; Scott A Lorch; Sara B DeMauro; Rachel G Greenberg; C Michael Cotten; Pablo J Sánchez; Edward F Bell; Eric C Eichenwald; Barbara J Stoll Journal: J Pediatr Date: 2020-06 Impact factor: 4.406
Authors: Joseph Schulman; Jochen Profit; Henry C Lee; Grace Dueñas; Mihoko V Bennett; Janella Parucha; Maria A L Jocson; Jeffrey B Gould Journal: Pediatrics Date: 2018-09 Impact factor: 7.124
Authors: Leena B Mithal; Ram Yogev; Hannah L Palac; Daniel Kaminsky; Ilan Gur; Karen K Mestan Journal: Early Hum Dev Date: 2018-01-23 Impact factor: 2.079
Authors: Dustin D Flannery; Sagori Mukhopadhyay; Erik A Jensen; Jeffrey S Gerber; Molly R Passarella; Kevin Dysart; Zubair H Aghai; Jay Greenspan; Karen M Puopolo Journal: J Pediatric Infect Dis Soc Date: 2021-03-26 Impact factor: 3.164
Authors: Maria S Rueda; Renzo Calderon-Anyosa; Jorge Gonzales; Christie G Turin; Alonso Zea-Vera; Jaime Zegarra; Sicilia Bellomo; Luis Cam; Anne Castaneda; Theresa J Ochoa Journal: Pediatr Infect Dis J Date: 2019-03 Impact factor: 2.129
Authors: Karen M Puopolo; Sagori Mukhopadhyay; Nellie I Hansen; C Michael Cotten; Barbara J Stoll; Pablo J Sanchez; Edward F Bell; Abhik Das; Angelita M Hensman; Krisa P Van Meurs; Myra H Wyckoff Journal: Pediatrics Date: 2017-10-05 Impact factor: 7.124